Furthermore, the significantly higher incidence of hypertension (32.3% vs. 23.7%), diarrhea (22.6% vs. 15.3%), and hand-foot syndrome (12.9% vs. 9.3%) in the combination therapy group aligns with the characteristic class effects of the VEGFR-targeted inhibitor lenvatinib. The gene discussed is KDR; the disease is Hand-foot syndrome.